阅读说明：本技术 抗老年痴呆药物及其制备方法 (Medicine for resisting senile dementia and its preparing method ) 是由 林德球 曾伍江 林洲 林筱雅 陈水春 陈华胜 于 2021-06-17 设计创作，主要内容包括：本申请属于医药技术领域,尤其涉及一种抗老年痴呆药物及其制备方法。其中,以所述抗老年痴呆药物的总质量为100％计,包括以下组分：岩藻糖30％～60％；黄芪多糖10％～40％；香菇多糖10％～40％；蛇毒神经生长因子20％～50％。本申请提供的抗老年痴呆药物,通过各组分的协同配合作用,对老年性痴呆有较好的治疗作用,能促进四肢躯干的乙酰胆碱释放,导致脑内的乙酰胆碱及多巴胺平衡,治疗和缓解老年性痴呆的症状,以及在一定程度上恢复智能和记忆。(The application belongs to the technical field of medicines, and particularly relates to an anti-senile dementia medicine and a preparation method thereof. Wherein the anti-senile dementia medicine comprises the following components by taking the total mass of the anti-senile dementia medicine as 100 percent: fucose 30% -60%; 10 to 40 percent of astragalus polysaccharide; 10 to 40 percent of lentinan; 20 to 50 percent of snake venom nerve growth factor. The application provides an anti-senile dementia medicine, through the synergistic effect of each component, has better treatment to senile dementia, can promote the acetylcholine release of four limbs trunk, leads to the acetylcholine and the dopamine balance in the brain, treats and alleviates senile dementia's symptom to and resume intelligence and memory to a certain extent.)

1. The medicine for resisting senile dementia is characterized by comprising the following components in percentage by mass of 100 percent of the total mass of the medicine for resisting senile dementia:

2. the anti-senile dementia drug according to claim 1, comprising the following components by 100% of the total mass of the anti-senile dementia drug:

3. the anti-senile dementia drug according to claim 2, wherein the mass ratio of the astragalus polysaccharide to the lentinan is 1 (1-3).

4. The anti-Alzheimer's disease drug according to any one of claims 1-3, wherein the snake venom nerve growth factor comprises at least one of bungarus venosus nerve growth factor, elapidae snake venom nerve growth factor, and Agkistrodon halys snake venom nerve growth factor.

5. The anti-senile dementia drug according to claim 4, wherein the mass ratio of the total mass of the fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is (2-4): 1;

and/or the mass ratio of the astragalus polysaccharide to the lentinan is 1: 3.

6. the anti-senile dementia drug according to claim 5, wherein the mass ratio of the total mass of fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is 3: 1;

and/or the anti-senile dementia medicine further comprises a pharmaceutic adjuvant, wherein the pharmaceutic adjuvant accounts for 1-3% by mass.

7. The anti-senile dementia drug according to claim 6, wherein the pharmaceutical excipients include at least one of a stabilizer, a thickener, a dispersant, a preservative, a disintegrant, a diluent, a flavoring agent, a lubricant, and an excipient.

8. The anti-senile dementia drug according to any one of claims 1 to 3 and 5 to 7, wherein the dosage form of the anti-senile dementia drug comprises at least one of a tablet, an injection and a capsule.

9. The preparation method of the anti-senile dementia medicine is characterized by comprising the following steps: mixing 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor, and preparing into pharmaceutically acceptable dosage forms.

10. The method of claim 9, wherein the step of formulating into a pharmaceutically acceptable dosage form comprises: adding adjuvant acceptable in medical scope into the mixture of fucose, Astragalus polysaccharides, lentinan and snake venom nerve growth factor, and making into at least one of tablet, injection and capsule.

Technical Field

The application belongs to the technical field of medicines, and particularly relates to an anti-senile dementia medicine and a preparation method thereof.

Background

Senile dementia, known under the name of Alzheimer's Disease (AD), was described by the german doctor Alois Alzheimer's in 1906 as the common cause of dementia, with an increasing prevalence with age, about 5% in people over 65 years and about 20% in people over 85 years. With the aging population, the incidence of AD increases year by year, seriously harms physical and mental health and life quality of the old, causes profound pain to patients, brings heavy burden to families and society, becomes a serious social problem, causes general attention of governments and medical circles of various countries, and is an urgent problem of modern medical research. In the case of senile dementia, it is generally considered that only decline occurs progressively due to organic or metabolic lesions of the brain. Recently, it is considered that brain metabolism disorder, dopamine decrease, and increase of Acetylcholine (ACH) are caused by various diseases, and the brain function is unbalanced, and mental disorder and action retardation instructed by the brain occur. In particular, in recent years, lipid diet is increased, physical exercise is reduced, cerebral vascular acidification is formed, and the like, which causes extensive encephalatrophy, cerebral blood flow supply insufficiency and senile dementia.

At present, no specific medicine exists for treating senile dementia, and the anti-AD medicine in clinical application or clinical research is mainly used for improving the ACH level in cranial nerves, recovering ACH nerve conduction, improving the memory, cognition and behavior ability of patients and delaying the development of diseases. One class of drugs is the cholinergic drugs, and the other class of drugs is the drugs that promote the release of ACH in the cranial nerves. The commonly used prevention and treatment medicines comprise medicines for promoting blood circulation and removing blood stasis, central stimulant, substance for improving cholinergic property, cerebral blood circulation improver and the like, however, the medicines have the defects of uncertain curative effect, weak specificity or large toxic and side effect, and the like, and the treatment of symptoms and root causes is not treated, so the application of the medicines is limited.

Disclosure of Invention

The application aims to provide an anti-senile dementia medicament and a preparation method thereof, and aims to solve the problems of inaccurate curative effect, low specificity and large toxic and side effects of the existing anti-senile dementia medicament to a certain extent.

In order to achieve the purpose of the application, the technical scheme adopted by the application is as follows:

in a first aspect, the present application provides an anti-senile dementia drug, which comprises the following components, based on 100% of the total mass of the anti-senile dementia drug:

further, the medicine comprises the following components by taking the total mass of the anti-senile dementia medicine as 100 percent:

furthermore, in the anti-senile dementia medicine, the mass ratio of the astragalus polysaccharide to the lentinan is 1 (1-3).

Further, the snake venom nerve growth factor comprises at least one of bungarus venom nerve growth factor, Elapidae snake venom nerve growth factor, and Pallas pit Viper venom nerve growth factor.

Further, the mass ratio of the total mass of the fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is (2-4): 1.

further, the mass ratio of the total mass of the fucose, the astragalus polysaccharide and the lentinan to the snake venom nerve growth factor is 3: 1.

further, the anti-senile dementia drug also comprises a pharmaceutic adjuvant, wherein the pharmaceutic adjuvant accounts for 1-3% by mass.

Further, the pharmaceutic adjuvant comprises at least one of a stabilizer, a thickening agent, a dispersing agent, a preservative, a disintegrating agent, a diluent, a flavoring agent, a lubricant and an excipient.

Furthermore, the dosage form of the anti-senile dementia drug comprises at least one of tablets, injections and capsules.

In a second aspect, the present application provides a method for preparing a medicament for resisting senile dementia, comprising the steps of: mixing 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor, and preparing into pharmaceutically acceptable dosage forms.

Further, the step of preparing a pharmaceutically acceptable dosage form comprises: adding adjuvant acceptable in medical scope into the mixture of fucose, Astragalus polysaccharides, lentinan and snake venom nerve growth factor, and making into at least one of tablet, injection and capsule.

In the anti-Alzheimer's disease drug provided by the first aspect of the application, 20% -50% of snake venom nerve growth factors can act on the postsynaptic part, namely, the motor nerve terminal blocks neuromuscular transmission, has competitive inhibition effect on acetylcholine, and plays a role with choline acetyltransferase in a specific neuron region, thereby effectively preventing damage of central cholinergic nerve systems, promoting the synthesis of acetylcholine and the generation of neuron growth and regeneration, and further solving the problem of reduction of acetylcholine in vivo caused by cholinergic neuron damage of senile dementia patients. In addition, 30 to 60 percent of fucose; 10 to 40 percent of astragalus polysaccharide is plant polysaccharide, can be used as an immune promoter or a regulator, and simultaneously has the functions of resisting virus, tumors, aging, radiation, stress, oxidation and the like; 10% -40% of lentinan is microbial polysaccharide, it has effects of antivirus, antitumor, regulating immunity function and stimulating interferon formation, etc., can enhance host immunity function, the mixed polysaccharide formed from these three kinds of polysaccharides can be combined with protein to form polysaccharide protein, in which the fucose can be used as component of sugar chain in the glucoprotein, can be combined with plasma membrane of various cell surfaces, can promote acetylcholine and dopamine metabolism in brain of patient to reach balance, repair necrotic starch protein, repair and rebuild immunity function, can be combined with snake venom nerve growth factor to play synergistic action, and can effectively prevent central cholinergic nerve system from damaging. The anti-senile dementia drug provided by the application has a better treatment effect on senile dementia through the synergistic cooperation effect of all the components, can promote the release of acetylcholine of limbs and trunk, leads to the balance of acetylcholine and dopamine in brain, treats and relieves the symptoms of senile dementia, and can restore intelligence and memory to a certain extent.

According to the preparation method of the anti-senile dementia drug provided by the second aspect of the application, 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor are mixed and processed to prepare pharmaceutically acceptable dosage forms, the preparation method is simple, the process is simple and convenient, and the preparation method is suitable for industrial large-scale production and application.

Detailed Description

In order to make the technical problems, technical solutions and advantageous effects to be solved by the present application more clearly apparent, the present application is further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present application and are not intended to limit the present application.

In this application, the term "and/or" describes an association relationship of associated objects, meaning that there may be three relationships, e.g., a and/or B, which may mean: a is present alone, A and B are present simultaneously, and B is present alone. Wherein A and B can be singular or plural. The character "/" generally indicates that the former and latter associated objects are in an "or" relationship.

In the present application, "at least one" means one or more, "a plurality" means two or more. "at least one of the following" or similar expressions refer to any combination of these items, including any combination of the singular or plural items. For example, "at least one (one) of a, b, or c," or "at least one (one) of a, b, and c," may each represent: a, b, c, a-b (i.e., a and b), a-c, b-c, or a-b-c, wherein a, b, and c may be single or plural, respectively.

It should be understood that, in various embodiments of the present application, the sequence numbers of the above-mentioned processes do not mean the execution sequence, some or all of the steps may be executed in parallel or executed sequentially, and the execution sequence of each process should be determined by its function and inherent logic, and should not constitute any limitation to the implementation process of the embodiments of the present application.

The terminology used in the embodiments of the present application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. As used in the examples of this application and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

The weight of the related components mentioned in the description of the embodiments of the present application may not only refer to the specific content of each component, but also represent the proportional relationship of the weight among the components, and therefore, the content of the related components is scaled up or down within the scope disclosed in the description of the embodiments of the present application as long as it is scaled up or down according to the description of the embodiments of the present application. Specifically, the mass in the description of the embodiments of the present application may be in units of mass known in the chemical industry, such as μ g, mg, g, and kg.

The first aspect of the embodiments of the present application provides an anti-alzheimer's disease drug, which comprises the following components, by taking the total mass of the anti-alzheimer's disease drug as 100%:

in the anti-Alzheimer's disease drug provided by the first aspect of the application, 20% -50% of snake venom nerve growth factors can act on the postsynaptic part, namely, the motor nerve terminal blocks neuromuscular transmission, has competitive inhibition effect on acetylcholine, and plays a role with choline acetyltransferase in a specific neuron region, thereby effectively preventing damage of central cholinergic nerve systems, promoting the synthesis of acetylcholine and the generation of neuron growth and regeneration, and further solving the problem of reduction of acetylcholine in vivo caused by cholinergic neuron damage of senile dementia patients. In addition, 30 to 60 percent of fucose; 10 to 40 percent of astragalus polysaccharide is plant polysaccharide, can be used as an immune promoter or a regulator, and simultaneously has the functions of resisting virus, tumors, aging, radiation, stress, oxidation and the like; 10% -40% of lentinan is microbial polysaccharide, it has effects of antivirus, antitumor, regulating immunity function and stimulating interferon formation, etc., can enhance host immunity function, the mixed polysaccharide formed from these three kinds of polysaccharides can be combined with protein to form polysaccharide protein, in which the fucose can be used as component of sugar chain in the glucoprotein, can be combined with plasma membrane of various cell surfaces, can promote acetylcholine and dopamine metabolism in brain of patient to reach balance, repair necrotic starch protein, repair and rebuild immunity function, can be combined with snake venom nerve growth factor to play synergistic action, and can effectively prevent central cholinergic nerve system from damaging. The anti-senile dementia drug provided by the embodiment of the application has a good treatment effect on senile dementia through the synergistic cooperation of the components, can promote the release of acetylcholine of limbs and trunk, leads to the balance of acetylcholine and dopamine in brain, treats and relieves symptoms of senile dementia, and can restore intelligence and memory to a certain extent.

In some embodiments, the anti-senile dementia drug comprises the following components by 100 percent of the total mass of the anti-senile dementia drug:

in the anti-senile dementia medicament in the embodiment of the application, the raw material components have better synergistic effect in the proportion, and have better curative effect on senile dementia. The fucoidin has multiple physiological activities of anticoagulation, blood fat reduction, chronic renal failure resistance, tumor resistance, virus resistance, tissue regeneration promotion, gastric ulcer inhibition, organism immunity enhancement and the like, and has physicochemical properties of heavy metal ion chelation, hydrophilicity and the like. In addition, the fucoidin has direct immunoregulation function on macrophages and T cells, has obvious pharmacological activities of anticoagulation, fibrinolysis promotion and the like, can induce cancer cell apoptosis, induce cell growth factor generation, promote cell growth, repair damaged or hypofunction organs and tissues and prevent thrombosis, also has good effects of reducing blood fat, blood sugar and cholesterol, is used as a binding agent and a suction resisting agent of metal ions, and can effectively reduce the absorption of harmful heavy metal ions such as lead and the like by a human body. Fucose, astragalus polysaccharide, lentinan and other plant polysaccharides can form proteoglycan with protein through covalent bond, exert biological function, and have the effects of regulating immunity, enhancing organism immunity, etc. Promoting the metabolism of acetylcholine and dopamine in brain of patients to reach balance, repairing necrotic starch protein, and repairing and reconstructing immunologic function; and can be combined with snake venom nerve growth factor to achieve synergistic effect, and effectively prevent central cholinergic nerve system damage.

In some embodiments, in the anti-alzheimer drug, the mass ratio of astragalus polysaccharide to lentinan is 1: (1-3). According to the embodiment of the application, the astragalus polysaccharide and the lentinan can improve the immunity of the organism by increasing the size of macrophages, have a certain relation with the concentration of the macrophage phagocytosis activity, and can promote the phagocytosis of the macrophages within a proper concentration range. Astragalus polysaccharides and lentinan can regulate macrophage function by regulating the secretion of cytokine and the activity of endoenzyme of macrophage. In addition, the astragalus polysaccharide and the lentinan can regulate the proliferation capacity, subgroup structure, cytokine secretion and the like of lymphocyte, improve the antibody level in the serum of animal organism, enhance the immune function of the organism, activate natural killer cells and enhance the killing activity of the natural killer cells. The mass ratio is 1: the astragalus polysaccharide and the lentinan in the step (1-3) have a better synergistic effect, and can enhance the immune function of an organism and improve the memory, cognition and behavior abilities of a patient. In some embodiments, the mass ratio of astragalus polysaccharides to lentinan is 1: 3.

in some embodiments, the snake venom nerve growth factor comprises at least one of bungarus venom nerve growth factor, Elapidae snake venom nerve growth factor, and Pallas pit Viper venom nerve growth factor. The snake venom nerve growth factors can induce the directional growth of nerve fibers, stimulate the development of cell bodies and dendrites, increase the density of nerve fiber innervating areas, promote the differentiation and development of neurons, increase the number of sensory nerves and sympathetic ganglia, increase the volume and prolong fibers, promote protein synthesis, sugar and lipid metabolism, promote the development of subcellular organelles, and particularly influence the expression and modification of structural and functional proteins closely related to nerve differentiation. Meanwhile, the snake venom nerve growth factors can maintain the requirement of axon regeneration after nerve injury, stimulate axon sprouting and synapse formation and promote the regeneration of nerve cells. Can cause the proliferation and the survival time of central cholinergic neurons to be prolonged, effectively protect the neurodegeneration caused by the damage of the cholinergic neurons, and improve the learning and cognitive functions. And can enhance specific and non-specific immune responses and modulate immune system function by affecting immune cell activity.

In some embodiments, the mass ratio of the total mass of fucose and plant polysaccharides to snake venom nerve growth factor is (2-4): 1. in the anti-senile dementia drug of the embodiment of the application, the mass ratio of the total mass of fucose, astragalus polysaccharide and lentinan to the mass of snake venom nerve growth factor is (2-4): 1, in some embodiments, the mass ratio of the total mass of fucose, astragalus polysaccharides, and lentinan to the snake venom nerve growth factor is 3: 1, the fucose, the plant polysaccharide and the snake venom nerve growth factor have the best synergistic effect in the mixture ratio.

In some embodiments, the anti-alzheimer disease drug further comprises a pharmaceutical adjuvant, and the pharmaceutical adjuvant accounts for 1-3% by mass. The anti-senile dementia drug further comprises a pharmaceutical adjuvant, and the drug can be prepared into different dosage forms according to actual application requirements through the matching of the auxiliary materials to be used. In some embodiments, the mass percentage of the pharmaceutical excipients may be 1%, 2%, 3%, etc.

In some embodiments, the pharmaceutical excipient comprises at least one of a stabilizer, a thickener, a dispersant, a preservative, a disintegrant, a diluent, a flavoring agent, a lubricant, and an excipient. The embodiment of the application has the advantages that the auxiliary materials are added into the medicinal auxiliary materials, so that the effects of disintegration, dilution, taste correction, lubrication, shaping and the like are achieved, the requirements of different preparations, tastes and the like are met, and the performances of the medicine such as use flexibility, taste, storage stability and the like are improved.

In some embodiments, the disintegrant is selected from: at least one of citric acid, sodium carbonate, sodium bicarbonate, sodium carboxymethyl starch and crospovidone, and these disintegrating agents can make the tablet rapidly break into fine particles in gastrointestinal fluid, so that the active substances in the anti-senile dementia drug can be rapidly dissolved and absorbed to exert drug effect.

In some embodiments, the diluent is selected from: dextrin sucrose, lactose, mannitol, and glucose. The diluent adopted by the embodiment of the invention has large medicine holding capacity, is used for increasing the weight and the volume of the tablet medicine, plays a filling role and is beneficial to forming of the pharmaceutical preparation.

In some embodiments, the flavoring agent is selected from: at least one of essence, mannitol, sorbitol, saccharin sodium, sodium cyclamate, aspartame, acesulfame-k essence, mannitol, sorbitol, saccharin sodium, sodium cyclamate, aspartame, and acesulfame-k. The flavoring agent adopted by the embodiment of the invention can better improve or shield the unpleasant smell and taste of the medicine, improve the taste of the medicine and enable patients to accept the medicine more easily.

In some embodiments, the lubricant is selected from: polyethylene glycol 6000, sodium dodecyl sulfate, magnesium dodecyl sulfate, L-leucine, and sodium benzoate. The lubricant adopted by the embodiment of the invention has the effects of glidant, anti-adhesion, lubrication and the like, and is beneficial to pharmaceutical preparation.

In some embodiments, the excipient is selected from: at least one of beeswax, guar gum, locust bean gum, konjac powder, carrageenan, lanolin, vaseline, polyethylene glycol, and magnesium lauryl sulfate. The excipient adopted by the embodiment of the invention has stable property, has no incompatibility with each active substance in the medicament, does not generate side effect, does not influence the curative effect, is harmless to human body, has no physiological effect, does not generate chemical or physical effect with each active substance of raw materials, and is not easy to deform, crack, mildew and the like at normal temperature.

In some embodiments, the stabilizing agent is selected from: xanthan gum, pectin, carrageenan, sodium carboxymethylcellulose, seaweed gel, cucurbituril, and animal protein. Wherein the animal protein is selected from one or more of bovine alpha-lactalbumin, bovine serum albumin, bovine beta-casein, bovine beta-lactoglobulin, fish skin gelatin, pig skin gelatin and chicken egg albumin. These stabilizers of the present application increase the stability of lycium barbarum, hippophae rhamnoides, nigella sativa seeds, almonds, hemp seeds, perilla seeds, wheat germs, borage and linseed in anti-senile dementia drugs.

In some embodiments, the thickening agent is selected from: the thickening agents can improve the viscosity of the system, keep the system in a uniform and stable suspension state or an opacified state, are beneficial to the formation of anti-senile dementia medicaments and are convenient to apply.

In some embodiments, the dispersant is selected from: at least one of vegetable oil, mineral oil and polyethylene glycol, and the dispersing agent can improve the mixing uniformity of the components in the composition.

In some embodiments, the preservative is selected from: the preservative has a good preservative effect, improves the storage stability of the anti-senile dementia drug, and prolongs the service life.

In some embodiments, the anti-alzheimer's disease drug dosage form comprises at least one of tablets, injections and capsules, and the dosage forms have wide application range and flexible application. In other embodiments, the composition can also be in the forms of oral liquid, paste, powder, granules, pills, suppositories and the like.

In some embodiments, the anti-senile dementia drug comprises the following components by 100 percent of the total mass of the anti-senile dementia drug:

the anti-senile dementia drug in the embodiment of the application can exert better curative effect through the synergistic effect of the components.

The anti-alzheimer's disease drug of the examples of this application can be prepared by the following methods of examples.

In a second aspect, the present application provides a method for preparing a medicament for resisting senile dementia, comprising the steps of: mixing 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor, and preparing into pharmaceutically acceptable dosage forms.

According to the preparation method of the anti-senile dementia drug provided by the second aspect of the application, 30-60 parts of fucose, 10-40 parts of astragalus polysaccharide, 10-40 parts of lentinan and 20-50 parts of snake venom nerve growth factor are mixed and processed to prepare a pharmaceutically acceptable dosage form, the preparation method is simple, the process is simple and convenient, and the preparation method is suitable for industrial large-scale production and application.

In some embodiments, the step of forming a pharmaceutically acceptable dosage form comprises: adding adjuvant acceptable in medical field into mixture of fucose, lentinan, Astragalus polysaccharides and snake venom nerve growth factor, and making into at least one of tablet, injection and capsule. The anti-senile dementia drug can be prepared into various dosage forms by adding different auxiliary materials, the preparation is flexible and convenient, no special limitation exists, the requirements of different dosage forms can be met, and the applicability is wide.

In order to make the above implementation details and operations clearly understood by those skilled in the art and to make the progress of the anti-alzheimer's disease drug and the preparation method thereof obviously appear in the examples of the present application, the above technical solutions are illustrated by a plurality of examples below.

Example 1

A medicine for resisting senile dementia is prepared by the following steps: mixing 35 parts of fucose, 20 parts of astragalus polysaccharide, 20 parts of lentinan and 25 parts of snake venom nerve growth factor, and making into tablet according to 500 microgram/granule of raw materials.

Further, in order to verify the advancement of the anti-senile dementia drugs of the examples of the present application, the following tests were performed on the anti-senile dementia drugs of the examples:

1. using the anti-senile dementia drug prepared in example 1 as an experimental group, setting three parallel experimental groups of 1 group, 2 groups and 3 groups, using physiological saline as a control group, administering the drug to experimental mice having symptoms of senile dementia by oral administration and intramuscular injection, recording the number of jumps of the mice after administration, and the test results are shown in the following table 1:

TABLE 1

From the test results, the anti-senile dementia drug prepared in the embodiment 1 of the application has the advantages that the number of jumping times is reduced after the drug is taken orally or through intramuscular injection, so that the drug can effectively inhibit the excitability of a nervous system, repair necrotic amyloid cells, regrow proteins and gradually recover memory. It is demonstrated that the anti-senile dementia drug prepared in example 1 of the present application shows a significant therapeutic effect on senile dementia. In addition, the P value of the anti-senile dementia drug prepared in the application example 1 is less than or equal to 0.01 in the test experiment, which shows that the error rate is low and the test result is close to real.

2. Clinical test of the anti-Alzheimer's disease drug prepared in example 1-clinical test

The medicine is administered to patients who are in a coma state, have limb movement disorder, have fever, can not speak, can not move, have incontinence of urine and feces at the time of admission, enter a vegetative state, and are clinically diagnosed as senile dementia.

The results show that: after the patient takes the anti-senile dementia drug in the embodiment 1 twice a day and two doses each time for 20 days, the mind can be recovered, and after the drug is taken for two months, the language can be recovered, and the meeting can be cleared.

3. Clinical test on the anti-Alzheimer's disease drug prepared in example 1

Is administered to patients with left cerebral thrombosis and vascular senile dementia.

The results show that: after the patient takes the anti-senile dementia drug in the embodiment 1 twice a day and two pills each time, the intelligence is active before half a month, the emotion is obviously active, after 2 months, the patient can speak, can walk and play, has good upper limb activity, can take care of people when meeting after three months, moves freely and has obvious improvement on self-care ability.

The above description is only exemplary of the present application and should not be taken as limiting the present application, as any modification, equivalent replacement, or improvement made within the spirit and principle of the present application should be included in the protection scope of the present application.